ArticleClinical epigenetics2017
Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis.
Article in Clinical epigenetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study.Clinical epigenetics · 2021Trial
- Decoding Dysregulation of DNA Methylation in Epigenetics of Idiopathic Pulmonary Fibrosis.Canadian respiratory journal · 2026Review
- Cell-free placental DNA: What do we really know?PLoS genetics · 2024Review
- Epigenetics Approaches toward Precision Medicine for Idiopathic Pulmonary Fibrosis: Focus on DNA Methylation.Biomedicines · 2023Review
- Metabolic requirements of pulmonary fibrosis: role of fibroblast metabolism.The FEBS journal · 2021Review
- The Crucial Role of NLRP3 Inflammasome in Viral Infection-Associated Fibrosing Interstitial Lung Diseases.International journal of molecular sciences · 2021Review
- Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.Scientific reports · 2021Article
- Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers.Scientific reports · 2021Article
- Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.Frontiers in medicine · 2021Review
- Mechanism of Fei-Xian Formula in the Treatment of Pulmonary Fibrosis on the Basis of Network Pharmacology Analysis Combined with Molecular Docking Validation.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression.Frontiers in molecular biosciences · 2021Article
- Air Pollution and Interstitial Lung Diseases: Defining Epigenomic Effects.American journal of respiratory and critical care medicine · 2020Article
- Article
- Insights into the Role of Bioactive Food Ingredients and the Microbiome in Idiopathic Pulmonary Fibrosis.International journal of molecular sciences · 2020Review
- A new nucleosomic-based model to identify and diagnose SSc-ILD.Clinical epigenetics · 2020Article
- EZH2 inhibition: a promising strategy to prevent cancer immune editing.Epigenomics · 2020Review
- Exosomal Long Non-Coding RNAs in Lung Diseases.International journal of molecular sciences · 2020Review
- The Organ Trail: A Review of Biomarkers of Organ Failure.Frontiers in oncology · 2020Review
- Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.Rheumatology (Oxford, England) · 2019Review
- Association between Plasma HMGB-1 and Silicosis: A Case-Control Study.International journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disorder of unknown origin with a highly variable and unpredictable clinical course. Polymorphisms and environmentally induced epigenetic variations seem to determine individual susceptibility to the development of lung fibrosis.
methodsWe have studied circulating epitopes on cell-free nucleosomes (cfnucleosomes) in 50 IPF patients. We have compared untreated IPF (
resultsOur findings showed that serum levels of bound HMGB1, mH2A1.1, 5mC, H3K9Ac, and H3K27Ac were significantly lower in IPF patients than in HS (
conclusionOur observations showed that cfnucleosomes (bound HMGB1, mH2A1.1, 5mC, H3K9Ac, and H3K27Ac) might have potential as biomarkers for diagnosis and treatment response. These results deserve further validation in longitudinal cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.